Kristopher A. Sarosiek

BCL-XL Dependence is a Subtype Agnostic Actionable Feature of Difficult-to-Treat Kidney Cancers

The paper identifies BCL-XL dependence as a common vulnerability in various kidney cancer subtypes and develops a model to predict it using biomarkers like AMPK activation.

A peptide-based screen for cell death inhibitors identifies the cytoprotective compound CDL36

The paper identifies CDL36, a compound that inhibits cell death by preventing mitochondrial outer membrane permeabilization, with potent cytoprotection against doxorubicin-induced toxicity.

Extracellular vesicles facilitate the horizontal transfer of drug resistance and stem-like properties between ovarian tumor cells

This study shows that extracellular vesicles from ovarian cancer stem cells or drug-resistant cells transfer stem-like properties and drug resistance to sensitive cells via EZH2 signaling.

Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms

This study identifies common survival mechanisms between drug-tolerant persisters and immunotherapy persisters, showing they share reduced mitochondrial apoptotic sensitivity and cross-resistance to therapies.

A molecular circuit regulates fate plasticity in emerging and adult AT2 cells

The paper identifies a molecular circuit involving C/EBP and Dlk1 that regulates fate plasticity in AT2 cells during lung development and injury.

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer

This study identifies that combining DHODH inhibition with BCL-XL targeting synergistically induces apoptosis in pancreatic cancer, offering a new combination therapy strategy.

Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-XL degradation to overcome cancer chemoresistance